Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes
Recruiting now · Phase 2
Conditions studied: Attention Deficit Disorder with Hyperactivity, Diabetes Mellitus, Type 1
In brief
This clinical trial aims to evaluate the safety and effectiveness of an intervention involving parental training in behaviour management and medication in children with both Type 1 Diabetes (T1D) and Attention Deficit Disorder with Hyperactivity (ADHD). ADHD is a neurodevelopmental disorder that affects around 5% of school-age children and adolescents, while T1D is a chronic disease requiring strict management. After initial parental training provided for parents/legal guardians, the children will be randomized to one of two cross-over groups, and treated with either lisdexamfetamine or methylphenidate first. After dose optimization for first 5-7 weeks, patients will be treated for 6 months total, after which they will be switched to the other drug. Researchers will then compare the ADHD symptom severity as measured by Conners 3 questionnaire, and compare the frequency of any adverse events associated with the therapy. As secondary outcomes, patient's T1D control and quality of life will be compared between the two drugs.
Key facts
- Study ID
- NCT05957055
- Run by
- Medical University of Lodz
- People needed
- 150
- Starts
- 2024-02-05
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2024-11-29
Who can join
Age: 8 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Pediatric Center of the Central Clinical Hospital of the Medical University of Lodz — Lodz, Łódź Voivodeship, Poland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.